Fig 1.
Representation and interpretation of the report from the Axonal application of the Spectralis optical coherence tomography in a control (left side) and in a patient with fibromyalgia and retina nerve fiber layer thinning (right side).
Table 1.
Epidemiologic and disease characteristics of 116 patients with fibromyalgia syndrome and 144 controls included in the study, and statistical significance of the comparisons between the groups (P).
Table 2.
Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with Fibromyalgia syndrome and controls, and statistical significance.
Fig 2.
Bar charts representing optical coherence tomography (OCT) measurements in eyes from 116 fibromyalgia patients and 144 controls.
A- Retinal nerve fiber layer measurements using the ganglion cell layer analysis of Cirrus OCT device. B- Retinal nerve fiber layer measurements using the Glaucoma analytic application of the Spectralis OCT device. C- Retinal nerve fiber layer measurements using the Nsite RNFL Axonal application of the Spectralis OCT device.
Table 3.
Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with early and advantage stages of Fibromyalgia syndrome and statistical significance with controls.
Table 4.
Mean and standard error of the mean of retinal nerve fiber layer thicknesses obtained with the Cirrus and Spectralis optical coherence tomography devices in patients with biologic fibromyalgia (26 patients), depressive fibromyalgia (34 patients), and atypical fibromyalgia (56 patients).